SeaSpine Holdings Corp
Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $191.5M | $154.3M | $36.1M | $33.2M | $131.8M | $128.9M |
| Operating income | −$61.0M | −$43.4M | −$39.2M | −$33.1M | −$32.7M | −$43.5M |
| Net income | −$54.3M | −$43.2M | −$9.0M | −$7.1M | −$9.1M | −$12.0M |
| Total assets | $377.3M | $214.4M | $141.7M | $172.3M | $134.5M | $147.2M |
| Total liabilities | $64.9M | $42.7M | $32.0M | $30.3M | $28.8M | $36.2M |
| Equity | $312.4M | $171.7M | $109.8M | $142.1M | $105.7M | $111.0M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 27.9M | 27.2M | 18.9M | 14.5M | 11.6M | 11.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −31.9%
- Net margin
- −28.4%
- Return on equity
- −17.4%
- Return on assets
- −14.4%
- Return on capital (ROCE)
- −18.8%
- Liabilities / assets
- 17.2%
- Debt / equity
- 0.21×
- Book value / share
- $11.18
- Revenue growth (YoY)
- 24.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- 4.09safe
- Accruals / assets
- −5.5%clean
- Beneish M-Score
- -1.33elevated
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Stephenson Kirtley C.Director | Jan 5, 2023 | D | 128,640 | — |
| Steinway AngelaDirector | Jan 5, 2023 | D | 23,725 | — |
| Maniar ShwetaDirector | Jan 5, 2023 | D | 23,993 | — |
| Gaeta ReneeDirector | Jan 5, 2023 | D | 36,056 | — |
| Fekete MichaelDirector | Jan 5, 2023 | D | 111,966 | — |
| Henneman John B IiiDirector | Jan 5, 2023 | D | 82,654 | — |
| Bradley KeithDirector | Jan 5, 2023 | D | 88,592 | — |
| Essig StuartDirector | Jan 5, 2023 | D | 460,275 | — |
| Winge John J.Officer — Vice President, Sales | Jan 5, 2023 | D | 90,951 | — |
| Lipschultz TylerOfficer — SVP, Orthobiologics and BD | Jan 5, 2023 | D | 131,284 | — |
| Keran Patrick LOfficer — SVP, General Counsel | Jan 5, 2023 | D | 69,628 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJan 5, 2023
- Shareholder voteJan 4, 2023
- Other material eventDec 27, 2022
- Results of operationsNov 1, 2022
- Results of operationsOct 11, 2022
- Entered a material agreement · Other material eventOct 11, 2022
- Results of operationsAug 2, 2022
- Entered a material agreementJul 18, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.